Supernus Pharmaceuticals, Inc.SUPNNASDAQ
LOADING
|||
Cash Generation Expanding
Trending higher, above historical average, strong compound growth.
Left:
||||
Operating cash flow minus capital expenditures
Latest
$171.23M
↑ 51% above average
Average (9y)
$113.46M
Historical baseline
Range
High:$171.23M
Low:$30.02M
CAGR
+21.3%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2024 | $171.23M | +54.9% |
| 2023 | $110.53M | -5.1% |
| 2022 | $116.41M | -6.9% |
| 2021 | $125.08M | -7.3% |
| 2020 | $134.95M | -3.9% |
| 2019 | $140.39M | +9.6% |
| 2018 | $128.14M | +13.8% |
| 2017 | $112.61M | +72.7% |
| 2016 | $65.21M | +117.2% |
| 2015 | $30.02M | - |